Pay in 4 interest-free payments of $6.22 Learn more
Ships within 48 hours · Estimated delivery Aug 24 - Aug 29
A short intake form will record your health history and objectives
Opdivo (nivolumab) Disease area(s): Oncology Manufacturer(s): Bristol Myers Squibb 2024 Sales (USD): $9.30 billion Why it sold so well: BMSs flagship immunotherapy, Opdivo, achieved strong sales in 2024 due to several key factors
A clearer, brighter complexion with an even tone
Every lot undergoes HPLC analysis confirming 99% purity, third-party verification by an independent laboratory, and identity confirmation
Biphasic Effects: Some users experience a temporary "detox flu" (headache or nausea) as toxins are released into the blood
US$ 26.63
US$ 27.43
US$ 27.77
US$ 23.98
